3/4
05:46 pm
rdhl
H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight
Low
Report
H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight
2/25
07:13 am
rdhl
Joint U.S. Commercialization of RedHill's Talicia® Commences [Yahoo! Finance]
Medium
Report
Joint U.S. Commercialization of RedHill's Talicia® Commences [Yahoo! Finance]
2/25
07:00 am
rdhl
Joint U.S. Commercialization of RedHill's Talicia® Commences
Medium
Report
Joint U.S. Commercialization of RedHill's Talicia® Commences
1/5
07:13 am
rdhl
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects [Yahoo! Finance]
High
Report
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects [Yahoo! Finance]
1/5
07:00 am
rdhl
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
High
Report
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
12/15
07:21 am
rdhl
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells [Yahoo! Finance]
Medium
Report
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells [Yahoo! Finance]
12/15
07:00 am
rdhl
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
Low
Report
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells